Treatment(s) already received-Chemotherapy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Chemotherapy Posts on Medivizor

Should children with ALL be revaccinated after chemotherapy?

Posted by on Mar 8, 2020 in Leukemia | 0 comments

In a nutshell This study evaluated the outcomes of vaccination in children with acute lymphoblastic leukemia (ALL). This study found that children had less vaccine protection after chemotherapy. Some background Vaccines help the immune system recognize a pathogen using dead or weakened bacteria or viruses. Vaccines are not effective if someone’s...

Read More

Is asparaginase-associated pancreatitis dependent on the age of patients with acute lymphoblastic leukemia?

Posted by on Jan 21, 2020 in Leukemia | 0 comments

In a nutshell This study evaluated whether the risk and severity of asparaginase-associated pancreatitis (AAP) depend on the age of patients with acute lymphoblastic leukemia (ALL). The main finding was that the AAP risk was higher in adolescents and adults compared to younger children. Some background Asparaginase (ASP; Oncaspar) is an important...

Read More

Evaluating ESHAO chemotherapy for patients with hard-to-treat Hodgkin’s lymphoma

Posted by on Jan 19, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of ESHAOx chemotherapy for patients with Hodgkin's lymphoma (HL) that has come back or stopped responding to treatment. This study found that this regimen is effective, with manageable side effects. Some background Most patients with HL respond well to initial treatment. However, some...

Read More

How effective and safe is acalabrutinib compared to other treatments for patients with mantle cell lymphoma?

Posted by on Nov 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness and safety of acalabrutinib (Calquence) to other targeted therapies for patients with mantle cell lymphoma (MCL). The authors found that acalabrutinib was just as safe and more effective for these patients. Some background MCL is a type of non-Hodgkin's lymphoma treated in...

Read More

Evaluating lenalidomide-based regimens for elderly patients with multiple myeloma

Posted by on Oct 30, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study compared different treatment combinations for first-line and maintenance therapies in elderly patients with multiple myeloma (MM). The authors found that first-line MPR was most effective for fit elderly patients, while all patients benefitted from RP maintenance therapy. Some background MM is a complex disease, and...

Read More

Is low dose leucovorin an effective and safe treatment option for colorectal cancer?

Posted by on Jul 30, 2019 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of low and high dose leucovorin (folinic acid) in the treatment of colorectal cancer. Researchers suggested that low dose leucovorin might be a safe treatment option for these patients. Some background Colorectal cancer is the fourth leading cause of death by cancer. This cancer frequently...

Read More

Searching for patients with triple negative breast cancer to test durvalumab and olaparib

Posted by on Jun 28, 2019 in Breast cancer | 0 comments

In a nutshell This phase 2 study will investigate the safety and effectiveness of olaparib (Lynparza) alone or in combination with durvalumab (Infinzi) in advanced triple negative breast cancer (TNBC). The main outcome will be progression-free survival (PFS). This study is recruiting in Durham, North Carolina, US. The details...

Read More